Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication.
By M. Okuda, Henning F. Horn, P. Tarapore, Yukari Tokuyama, A. Smulian, P. Chan, E. Knudsen, Irene A Hofmann, J. D. Snyder, K. Bove and 1 more. Cell, 2000
743 citations recorded by the source corpus.
Subfields: Cell Biology, Genetics, Oncology
View Paper: https://www.semanticscholar.org/paper/83de89e3867e021cf48960d044a25bb3380c7448
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cell Biology
In Genetics
In Oncology
Citations in the corpus
- Cyclin E ablation in the mouse. (2003, neutral): “It is widely assumed that the two trosome duplication (nucleophosmin) (Hinchcliffe et al., 1999; Okuda et al., 2000 ), histone biosynthesis (p220”
- Nucleophosmin and cancer (2006, background): “During the cell cycle, the phosphorylation state of NPM is modified by a number of protein kinase”
- Cyclin-dependent kinase pathways as targets for cancer treatment. (2006, background): “Although Rb is the primary target of cyclin D–dependent kinases, cyclin E–cdk2 phosphorylates other targets as well, including p27,(20,21) which further facilitates S-phase entry, p220 nuclear protein mapped to the Ataxia Telanglectasia locus (), which stimulates replication-dependent histone gene t”